Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02117219 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT02117219 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 67 participants.
The verdict
NCT02117219, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome after treatment with hypomethylating agents
Interventions
- BIOLOGICAL tremelimumab
- BIOLOGICAL MEDI4736 Evaluate MEDI4736 in MDS
- DRUG VIDAZA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2014-05-20 |
| Est. Completion | 2019-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02117219
The ClinicalTrials.gov registry entry for NCT02117219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which tremelimumab is the first listed.
NCT02117219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02117219 about?
NCT02117219 is a clinical study titled "Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome". This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome after treatment with hypomethylating agents
What is the current status of trial NCT02117219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2014-05-20. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT02117219?
The interventions under investigation include: tremelimumab (BIOLOGICAL), MEDI4736 Evaluate MEDI4736 in MDS (BIOLOGICAL), VIDAZA (DRUG).
Who is sponsoring clinical trial NCT02117219?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.